These data suggest that the reductions in BMPR1B and BMPR2, and the increase in BMPR1A, that are associated with both stage 4 NB and MYCN-amplified NB may combine to drive cells towards a fate involving failure of differentiation and promotion of proliferation. The gene discussed is MYCN; the disease is neuroblastoma.